GlassScriptPhysician profile
Chacko Jose Alappatt
NPI 1477584399
$257,751.86
in general payments reported to CMS, 2019-2025
43 companies · $34K in 2025
The $34K reported for 2025 was more than what 95% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $56K · 2021: $40K · 2022: $14K · 2023: $10K · 2024: $22K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Food and Beverage: $12K · Consulting Fee: $11K · Travel and Lodging: $3,721 · Honoraria: $3,125 · Education: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,175.00 |
| Food and Beverage | $11,723.11 |
| Consulting Fee | $10,570.00 |
| Travel and Lodging | $3,720.70 |
| Honoraria | $3,125.00 |
| Education | $346.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $57,562.57 | 2019-2023 | Krystexxa |
| Ucb, INC. | $56,736.51 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $52,001.47 | 2019-2025 | Taltz, Zepbound |
| Amgen INC. | $34,164.06 | 2019-2025 | Krystexxa, Evenity, Tavneos |
| Glaxosmithkline, LLC. | $15,563.45 | 2019-2025 | Benlysta |
| Celgene Corporation | $13,651.82 | 2019 | |
| Abbvie INC. | $8,660.65 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Janssen Biotech, INC. | $6,347.85 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Sobi, INC | $4,768.99 | 2022-2025 | |
| Medexus Pharma, INC. | $1,756.45 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,451.39 | 2019-2025 | Ofev, Cyltezo |
| Mallinckrodt Hospital Products INC. | $635.79 | 2020-2025 | Acthar |
| Pfizer INC. | $584.75 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $578.00 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $531.51 | 2022-2025 | Purified Cortrophin Gel |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $316.36 | 2022-2025 | Saphnelo, Flumist Quadrivalent |
| Radius Health, INC. | $315.11 | 2019-2024 | Tymlos |
| Genentech USA, INC. | $268.30 | 2019-2025 | Gazyva |
| Aurinia Pharma U.S., INC. | $261.75 | 2021-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $195.66 | 2019-2025 | Orencia |
| Mallinckrodt Enterprises LLC | $181.19 | 2019 | |
| Alexion Pharmaceuticals, INC. | $180.75 | 2023-2025 | Strensiq, Ultomiris |
| Actelion Pharmaceuticals US, INC. | $147.14 | 2019-2022 | |
| Octapharma USA, INC. | $133.89 | 2022-2025 | Octagam Immune Globulin (Human), Panzyga |
| Arcutis Biotherapeutics, INC. | $82.21 | 2023 | |
| Antares Pharma, INC. | $77.85 | 2019-2020 | |
| Organon LLC | $73.96 | 2021-2025 | Hadlima, Renflexis, Nexplanon |
| Regeneron Healthcare Solutions, INC. | $71.39 | 2019 | |
| Fresenius Kabi USA, LLC | $70.26 | 2023-2024 | Idacio |
| Invivyd INC | $67.78 | 2025 | Pemgarda |
| Genzyme Corporation | $66.00 | 2020-2025 | |
| Pacira Therapeutics, INC. | $44.33 | 2020-2021 | |
| Cardinal Health INC | $42.85 | 2024 | |
| Mylan Institutional INC. | $37.90 | 2023 | Hulio |
| Merck Sharp & Dohme LLC | $29.18 | 2020-2021 | |
| Oxford Immunotec USA INC | $19.70 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $17.52 | 2025 | |
| Bioventus LLC | $15.47 | 2020 | |
| Sandoz INC. | $15.02 | 2023 | Hyrimoz |
| Scilex Pharmaceuticals INC. | $13.93 | 2025 | |
| Sanofi-Aventis U.S. LLC | $11.10 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chacko Alappatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.